UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Iodine-131-MIBG therapy of a patient with carcinoid liver metastases

Prvulovich, EM; Stein, RC; Bomanji, JB; Ledermann, JA; Taylor, I; Ell, PJ; (1998) Iodine-131-MIBG therapy of a patient with carcinoid liver metastases. J NUCL MED , 39 (10) 1743 - 1745.

Full text not available from this repository.


Iodine-131-metaiodobenzylguanidine (MIBG) is highly concentrated by >60% of carcinoid metastases and thus provides a therapeutic oppportunity. Methods: A symptomatic patient with carcinoid liver metastases, unresponsive to chemotherapy combined with interferon-alpha, was subsequently treated with I-131-MIBG. Results: Radionuclide therapy, which was without significant side effects, resulted in symptomatic improvement and reduced urinary 5-hydroxyindoleacetic acid levels. No new metastases were observed for 15 mo after I-131-MIBG therapy. Gross cystic change occurred in existing liver metastases, presumably as a result of ischemic necrosis. Surgical deroofing and aspiration of cysts led to regeneration of normal liver tissue. Conclusion: Iodine-131-MIBG therapy can provide prolonged symptomatic relief and improved quality of life in patients with metastatic carcinoid disease unresponsive to other therapies. The antitumor effect of I-131-MIBG was accompanied by few side effects, suggesting that this therapy should be considered in symptomatic patients with an early stage of disease.

Type: Article
Title: Iodine-131-MIBG therapy of a patient with carcinoid liver metastases
Keywords: iodine-131 metaiodobenzylguanidine, liver carcinoid, pseudocyst, TUMORS, METAIODOBENZYLGUANIDINE
URI: http://discovery.ucl.ac.uk/id/eprint/55475
Downloads since deposit
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item